By Counterforce Health Team in Acthar Gel (repository corticotropin injection) —

How to Get Acthar Gel Approved by UnitedHealthcare in California: Prior Authorization Guide & Appeal Process

Answer Box: Getting Acthar Gel Covered by UnitedHealthcare in California

UnitedHealthcare requires prior authorization for Acthar Gel (repository corticotropin injection) with strict medical necessity criteria limited to infantile spasms under age 2 and opsoclonus-myoclonus syndrome. Step therapy requiring documented failure of high-dose corticosteroids is mandatory for most conditions. If denied, California residents can file internal appeals (180 days) then request Independent Medical Review through the Department of Managed Health Care. First step today: Verify your specific indication meets UHC's Repository Corticotropin Injection policy and gather documentation of prior steroid trials.

Table of Contents

When Alternatives Make Sense

UnitedHealthcare's restrictive coverage of Acthar Gel reflects the medical evidence: most clinical studies show repository corticotropin performs no better than high-dose synthetic corticosteroids for conditions like multiple sclerosis relapses, while costing tens of thousands more per treatment course.

For many patients, switching to alternatives isn't just about insurance approval—it's about accessing treatments with stronger evidence and fewer logistical barriers. High-dose methylprednisolone or prednisone can be administered in shorter courses (3-5 days vs. 2+ weeks for Acthar) with similar efficacy for MS exacerbations.

Consider alternatives when:

  • Your condition responds well to conventional corticosteroids
  • Injection frequency is a concern (Acthar requires daily IM injections)
  • Insurance repeatedly denies coverage despite appeals
  • Cost is a significant barrier even with manufacturer support

Typical Formulary Alternatives

For Multiple Sclerosis Exacerbations

High-dose corticosteroids remain the gold standard:

  • Methylprednisolone: 500-1000mg IV daily for 3-5 days
  • Prednisone: 1250mg oral daily (equivalent dosing)
  • Clinical studies show these achieve similar relapse recovery rates to Acthar Gel with fewer side effects

For Infantile Spasms

Evidence-based first-line options:

  • High-dose prednisolone: Studies suggest similar efficacy to ACTH for short-term spasm control
  • Vigabatrin: Preferred first-line for tuberous sclerosis-related infantile spasms
  • Synthetic ACTH analogs: Where available, may offer cost savings over repository corticotropin

For Rheumatologic Conditions

Standard disease-modifying approaches:

  • Methotrexate: First-line DMARD for rheumatoid arthritis with strong evidence
  • Rituximab: Effective for seropositive RA and certain vasculitis conditions
  • High-dose pulse steroids: For acute flares of lupus or other autoimmune conditions
Note: The shift toward these alternatives reflects both cost considerations and clinical evidence. Professional societies increasingly recommend against routine Acthar use when synthetic corticosteroids are available and tolerated.

Coverage Requirements at a Glance

Requirement What It Means Source
Prior Authorization Required for all indications UHC PA Policy
Age Restriction Must be under 2 years for infantile spasms UHC Medical Necessity Criteria
Step Therapy Documented high-dose steroid failure required UHC Clinical Policy
Duration Limits 4 weeks (infantile spasms), 3 months (OMS) UHC Authorization Guidelines
Reauthorization Generally denied; requires appeals process UHC Policy Updates 2024-2025
Formulary Status Tier 3 with PA and non-dose-specific step therapy OptumRx Formularies

Step-by-Step: Fastest Path to Approval

1. Verify Coverage Criteria

Who: Patient or clinic staff
Action: Review UHC's current Repository Corticotropin policy
Timeline: Same day
Key check: Confirm your diagnosis is listed as covered (infantile spasms <2 years, opsoclonus-myoclonus syndrome)

2. Document Step Therapy Requirements

Who: Prescribing physician
Action: Gather records of high-dose corticosteroid trials with specific doses, duration, and response
Timeline: 1-3 days
Required: Drug names, exact dosing, start/stop dates, reasons for discontinuation

3. Submit Prior Authorization

Who: Healthcare provider
Action: Complete PA through UnitedHealthcare Provider Portal or fax submission
Timeline: Submit within 24-48 hours of prescription
Include: Diagnosis codes, treatment history, medical necessity rationale

4. Request Peer-to-Peer Review

Who: Prescribing physician
Action: If initial denial, request direct discussion with UHC medical director
Timeline: Within 72 hours of denial
Success rate: Appeals with peer-to-peer review succeed 78-85% of the time

5. File Internal Appeal

Who: Patient or provider
Action: Submit written appeal with additional clinical documentation
Timeline: Within 180 days of denial
Format: Via portal, fax, or mail with denial letter attached

6. Escalate to Independent Medical Review

Who: Patient
Action: Request IMR through California DMHC
Timeline: After internal appeal completion or 30-day response period
Cost: Free to patient; binding decision

7. Monitor and Document Response

Who: Healthcare team
Action: Track clinical outcomes during any approved treatment period
Purpose: Support future reauthorization requests or alternative therapy decisions

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
"Step therapy not met" Provide detailed steroid trial history Drug names, doses, dates, response measures, adverse events
"Not medically necessary" Submit specialist consultation and guidelines Neurologist/rheumatologist notes, relevant society guidelines
"Insufficient information" Resubmit with complete clinical picture Diagnosis confirmation, EEG results, functional assessments
"Experimental/investigational" Cite FDA labeling and UHC policy FDA indication language, UHC coverage criteria
"Exceeds quantity limits" Justify duration with clinical urgency Treatment protocol rationale, monitoring plan

Appeals Process for California Residents

California's dual regulatory system provides robust appeal rights for UnitedHealthcare members:

Internal Appeals (First Level)

  • Timeline: 180 days from denial to file
  • Response time: 30 days standard, 72 hours expedited
  • Submit via: UHC member portal, fax, or mail
  • Required: Original denial letter, new clinical evidence, written appeal letter

Independent Medical Review (IMR)

California residents can request IMR through the Department of Managed Health Care after completing internal appeals:

  • Eligibility: Medical necessity denials, experimental/investigational determinations
  • Timeline: 45 days for standard review, 72 hours for expedited
  • Success rate: 57.9% overturn rate for specialty drug denials
  • Contact: DMHC Help Center at 888-466-2219
California Advantage: The state's IMR process is free to patients and uses independent physician experts in the relevant specialty. Insurers must comply with IMR decisions.

Medical Necessity Documentation

Clinician Corner: Essential Elements

When preparing medical necessity letters for Acthar Gel, include these critical components:

Clinical Problem Statement:

  • Specific diagnosis with ICD-10 codes
  • Disease severity and functional impact
  • Urgency of treatment need

Prior Treatment History:

  • Complete list of corticosteroid trials (prednisone, methylprednisolone, IV steroids)
  • Exact dosing regimens and duration
  • Objective response measures (seizure frequency, EDSS scores, inflammatory markers)
  • Specific adverse events or contraindications

Medical Necessity Rationale:

  • Why Acthar is clinically appropriate for this patient
  • Expected benefits beyond standard therapies
  • Monitoring plan and follow-up schedule

Guideline Support:

  • Relevant specialty society recommendations
  • FDA labeling information
  • Peer-reviewed literature citations

Cost Considerations & Patient Support

Acthar Gel represents one of the highest-cost specialty medications, with single vials typically costing tens of thousands of dollars. Understanding financial resources is crucial:

Manufacturer Support

  • Acthar Patient Support Program: Benefit verification and PA assistance
  • Contact: Acthar.com patient support
  • Limitations: Cannot override insurance criteria but may help with documentation

Alternative Financial Resources

  • Foundation grants: Patient Access Network (PAN), HealthWell Foundation
  • State programs: California may have additional specialty drug assistance
  • Clinical trials: Consider research participation for investigational alternatives

Counterforce Health specializes in turning insurance denials into targeted appeals by analyzing denial letters, plan policies, and clinical notes to identify the specific denial basis and draft evidence-backed rebuttals. Their platform helps patients and clinicians navigate complex prior authorization requirements and appeals processes for high-cost specialty medications like Acthar Gel.

Cost-Effectiveness Considerations

Recent analyses suggest that for many conditions, high-dose synthetic corticosteroids provide equivalent clinical outcomes at a fraction of the cost. This evidence increasingly influences payer policies and clinical guidelines.

FAQ

How long does UnitedHealthcare PA take in California?
Standard prior authorizations receive responses within 72 hours for urgent requests and 15 days for non-urgent. Expedited reviews are available when treatment delay could jeopardize health.

What if Acthar Gel is non-formulary on my plan?
Request a formulary exception through your provider, emphasizing medical necessity and failed alternatives. Non-formulary doesn't mean automatic denial if clinical criteria are met.

Can I request an expedited appeal in California?
Yes, if your health condition could be seriously jeopardized by delay. Both UnitedHealthcare internal appeals and California IMR offer expedited timelines (72 hours).

Does step therapy apply if I failed steroids outside California?
Yes, UnitedHealthcare accepts documentation of prior steroid trials from any state, provided the records include specific dosing, duration, and response details.

What's the success rate for Acthar Gel appeals?
While specific Acthar data isn't published, UnitedHealthcare written appeals succeed at 67% overall, rising to 78-85% with peer-to-peer review. California's IMR process shows 57.9% success for specialty drug medical necessity denials.

How do I know if my condition qualifies for coverage?
Review UnitedHealthcare's Repository Corticotropin policy. Currently covered indications are primarily limited to infantile spasms under age 2 and opsoclonus-myoclonus syndrome.

Can my doctor request a peer-to-peer review?
Yes, physicians can request direct consultation with UnitedHealthcare medical directors. This significantly improves approval rates and should be requested promptly after any denial.

What happens if I'm approved but need to continue treatment?
UnitedHealthcare increasingly denies reauthorizations by default, requiring appeals even for responding patients. Document clinical improvement thoroughly during initial treatment periods.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan benefits and clinical circumstances. Always consult with your healthcare provider and insurance plan for specific guidance. For assistance with appeals and coverage disputes, contact the California Department of Managed Health Care at 888-466-2219 or visit healthhelp.ca.gov.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.